1-3 of 3
Luis Lopez-Gomez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

90Y-Ibritumomab-Tiuxetan Consolidation in First-Line Complete Response Follicular Lymphoma Patients. Single Center Outcomes Analysis after Five Years Median Follow-up

Marcio Andrade-Campos, MD PhD, Natalia Espinosa-Lara, MD, Paola Lievano, MD PhD, Luis Lopez-Gomez, MD PhD, Teresa Baringo, MD, Pilar Giraldo, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5323.
https://doi.org/10.1182/blood.V128.22.5323.5323
Published: 2016
Journal Articles

NCCN-IPI in Patients with Diffuse Large B CELL Lymphoma Treated with DA-R-EPOCH. Retrospective Analysis

Juan Miguel Bergua Burgues, Luis Lopez-Gomez, MD PhD, Fatima Ibañez, MD, Sara Suarez-Varela, MD, Julio Prieto-Fernandez, Fernando Carnicero, Ignacio Casas, MD, Maria Luisa Martín-Mateos, Carmen Cabrera, María José Arcos-Carmona, MD, M Helena Bañas, MD, Nuria Bermejo, MD, Miguel A. Sanz, MD PhD, Sara Bobillo-Varela, MD, Andres Lopez
Journal: Blood
Blood (2016) 128 (22): 5401.
https://doi.org/10.1182/blood.V128.22.5401.5401
Published: 2016
Journal Articles

RIT with 90Y Ibritumomab Tiuxetan in Agressive Non-Hodgkin Lymphoma. Evaluation of Recent Outcomes in a Single Institution

Anel Montes, MD, Ma Andrade, Ilda Murillo, MD, Luis Lopez-Gomez, Teresa Baringo, MD, PhD, Pilar Giraldo
Journal: Blood
Blood (2012) 120 (21): 4883.
https://doi.org/10.1182/blood.V120.21.4883.4883
Published: 2012